To our knowledge, our results have demonstrated for the first time that simvastatin could markedly suppress secretion of IL-17A and IL-22, which may contribute to decreased IL-6 and CXCL8 production in the airways of patients with COPD. This evidence concerns the gene CXCL8 and chronic obstructive pulmonary disease.